EP3600243A1 - Forme dépôt extrudée pour la libération prolongée de substance active - Google Patents

Forme dépôt extrudée pour la libération prolongée de substance active

Info

Publication number
EP3600243A1
EP3600243A1 EP18714741.8A EP18714741A EP3600243A1 EP 3600243 A1 EP3600243 A1 EP 3600243A1 EP 18714741 A EP18714741 A EP 18714741A EP 3600243 A1 EP3600243 A1 EP 3600243A1
Authority
EP
European Patent Office
Prior art keywords
depot form
extruded
extruded depot
melting
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18714741.8A
Other languages
German (de)
English (en)
Inventor
Alexandra PARTENHAUSER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMW GmbH
Original Assignee
AMW GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AMW GmbH filed Critical AMW GmbH
Publication of EP3600243A1 publication Critical patent/EP3600243A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Definitions

  • the present invention relates to an extruded depot form comprising at least one active ingredient and a combination of at least two compounds of the lipase-degradable substances, the at least two compounds comprising a low-melting compound and a high-melting compound. Furthermore, the present invention relates to a process for the production of the extruded depot form and the use of the extruded depot form.
  • Subcutaneous dosage forms generally include liquid or solid formulations which can be administered by injection or surgery into the subcutaneous tissue. Solid formulations are usually administered as cylindrical polymer rods with drug embedded therein. Forms of administration which deliver active substances over a period of several days to, for example, 24 months are also referred to as depot dosage forms.
  • Substances released from depot dosage forms are not subject to the so-called first-pass effect, ie they do not pass through the digestive tract and the liver and, moreover, can ensure a continuous release of active ingredient over a sustained period of time. In this way, large fluctuations in drug concentration and associated side effects are avoided, which occur, for example, often in intravenous dosage forms.
  • the controlled, sustained release of sustained release drug formulations may extend the application interval, and depot pharmaceutical forms that are biodegradable must not be removed after the intended application time, these properties make subcutaneous depot forms user-friendly drugs.
  • the drug release rate and duration from depot forms may be affected by additives included in the formulation, with long term formulations requiring high biocompatibility of the ingredients to minimize patient health impairment.
  • WO 2005 102 284 discloses a formulation comprising a protein agent, a biodegradable polymer and a lipid which is solid at room temperature.
  • WO 2004 01 1 054 describes an injectable depot molding formulation comprising a plurality of biocompatible and biodegradable polymers and a substance for forming a gel in which an active ingredient is dispersed.
  • an extruded depot form which comprises at least one active ingredient and at least two compounds from the class of lipase-degradable substances, wherein the at least two compounds comprise a low-melting compound and a high-melting compound according to claim 1, and by a method for Production of the depot form according to the invention according to claim 1 1. Furthermore, the object is achieved by a composition according to the invention for use according to claim 15. The present invention therefore relates to an extruded sustained-release depot form
  • Ratio of the low-melting compound to the high-melting compound in the range of 1: 9 to 9: 1, preferably in the range of 1: 3 to 5: 1, and,
  • Inventive extruded depot forms according to claim 1 advantageously have a controlled release of active ingredient in a period of one week to one year, a high biocompatibility and a good biodegradability.
  • the term biodegradability is understood to mean that substances contained in the formulation are degraded or eroded in vivo for example by enzymatic, chemical or physical processes into smaller units.
  • the depot forms according to the invention comprise at least one active substance and at least two compounds from the class of lipase-degradable substances, as well as optional auxiliaries.
  • the dry weight of the at least two compounds from the class of lipase-degradable substances and optionally of the at least one adjuvant contained a proportion of more than 60 wt .-%, preferably of more than 62 wt .-%, more preferably of more than 64 Wt .-%, particularly preferably of at least 65 wt .-%, of the total weight of the depot form.
  • the dry weight of the depot form here refers to the weight of a formulation ready for administration, which has no or a negligible content, in particular less than 3% by weight, of water.
  • the total content of the at least two compounds from the class of lipase-degradable substances comprises the content of all compounds from the class of lipase-degradable substances in the active ingredient-containing depot form.
  • the dry weight of the at least two compounds from the class of lipase-degradable substances and optionally of the at least one adjuvant contained has a maximum content of 99 wt .-%, preferably of at most 97.5 wt .-%, particularly preferably of at most 95 wt .-%, more preferably of about 90 wt .-%, of the total weight of the depot form.
  • a first compound from the class of lipase-degradable substances has a lower melting point than a second compound from the class of lipase-degradable substances, the Ratio of at least two compounds to each other is an essential feature of the invention.
  • the ratio of the at least two compounds of the class of lipase degradable substances to the ratio of the dry weight of a low melting compound in the depot form refers to the dry weight of a refractory compound present in the depot form.
  • the ratio of a low-melting to a high-melting compound is in the range from about 1: 9 to about 9: 1, preferably in the range from about 1: 6 to about 6: 1, particularly preferably in the range from about 1: 3 to about 5: 1 .
  • a first compound of the class of lipase-degradable substances having a lower melting point is referred to as a "low-melting compound”
  • a second compound of the class of lipase-degradable substances having a higher melting point is referred to as a "high-melting compound”.
  • lipases refers to enzymes that are able to cleave lipids, lipases belong to the family of esterases and catalyze the hydrolysis of fats to fatty acids and glycerines, for example lipoprotein lipase is relevant for the degradation of subcutaneous depot forms.
  • a depot form according to the invention may contain at least one adjuvant which can influence the release of active ingredient from the depot form, the active ingredient stability, the plasma half-life and / or the bioavailability of the at least one active substance.
  • a preferred adjuvant supports the controlled release of the at least one active substance from the depot form.
  • such an adjuvant contributes to a long-lasting release of active ingredient, without, however, adversely affecting biocompatibility.
  • the addition of such an adjuvant may improve the stability of the active ingredient contained in the depot form.
  • the depot form is intended for a long-lasting application of several weeks to one year.
  • the extruded depot form according to the invention releases the at least one active ingredient from the active ingredient-containing depot form to the surrounding tissue, with a substantial portion of the active ingredient being absorbed systemically.
  • a substantial proportion of the active ingredient can advantageously be dispensed into the tissue surrounding the application site.
  • the absolute amount of drug contained in the depot form generally determines the length of time in which continuous delivery of the drug into or onto the organism is maintained. Therefore, the highest possible loading of the depot form with at least one active ingredient is desirable when the application time of the depot form is long, d. H. several weeks to twelve months.
  • An extruded depot form according to the invention is preferably used for an application period of at least one week to a maximum of 12 months, preferably for an application duration of one week to 6 months, in particular for an application period of 2 weeks to 3 months.
  • the present invention thus relates to the medical, veterinary and / or cosmetic use of the depot form according to the invention for delivering active substances into the bloodstream of a human or animal body.
  • the present invention relates to a method for producing a depot form according to the invention, the method comprising the following steps:
  • a homogeneous mixture can be produced by a suitable mixing process, preferably without the addition of solvents.
  • the mixing process may moreover comprise more than one step, for example by first preparing a mixture of the low-melting and the high-melting compound and, separately therefrom, a mixture of the at least one adjuvant and the at least one active substance, which are mixed together in a second step.
  • the homogeneous mixture thus obtained is then heated to a temperature which is lower than the temperature of the melting point of each high-melting compound used, and then extruded by extrusion, in particular by melt extrusion, to obtain the extrudate or the core.
  • a homogeneous coating mixture or composition which consists of at least one of the abovementioned components (i) of the depot form according to the invention, is optionally carried out.
  • the components according to (i) comprise at least 60% by weight of the dry weight of the depot form according to the invention, preferably at least 62% by weight, more preferably at least 64% by weight, especially preferably at least 65% by weight, of the total weight of the Depot form according to the invention.
  • the preparation of the depot form according to the invention can therefore be carried out at temperatures at which even thermosensitive agents can be processed without impairment.
  • This is of particular interest for protein drugs and the like.
  • an advantageous production method can provide for sterilization of the extruded depot form according to the invention before a possible packaging step.
  • a depot form according to the invention can also be produced without a sterilization process or else under conditions which are not aseptic.
  • the extruded depot mold according to the invention can be subjected to a packaging process in which the depot mold, after a possible sterilization process, is packed directly into a packaging unit.
  • the extruded depot form can also be initially introduced into an applicator provided for application of the depot form according to the invention and packaged together with the latter in a packaging unit.
  • the present invention comprises an extruded depot mold obtainable by a method as described above.
  • a preferred extruded depot form comprises a low-melting compound and a high-melting compound, wherein the melting point of a low-melting compound at a maximum of 45 ° C, preferably at 44 ° C, especially below 43 ° C and / or the melting point of a high-melting compound at 45 ° C, preferably at least 50 ° C, in particular at least 60 ° C. More preferably, the low melting compound has a melting point of from about 30 to about 43 ° C, and the high melting compound has a melting point of from about 46 to about 75 ° C.
  • the difference in melting points between the at least two compounds varies from the class of lipase degradable substances in a range of about 1 to about 45 ° C.
  • the difference in melting points between the low-melting and high-melting compounds is present from about 2 to about 40 ° C, more preferably from about 5 to about 35 ° C, more preferably from about 10 to about 32.5 ° C, most preferably from about 15 to about 30 ° C.
  • both the low-melting and the high-melting compounds are selected from mono-, di- and / or triglycerides, for example esterifications of glycerol with saturated or unsaturated fatty acids of 5 to 20 carbon atoms, phosphatidic acid, lecithin, phosphatidylethanolamine, phosphatidylinositol, Phosphatidylserine, diphosphatidylglycerol, ceramides, cerebrosides, gangliosides, sphingophospholipids, sphingomyelins, sphingosulphatides, glycosphingosides, acylamino sugars, acylamino sugaredglycans, acyltrehaloses, acyltrehaloseglycans, sorbitan fatty acid esters, squalene, steroids, polyketides, sterolipids, prenollipids, cholesterol, hard fats,
  • Examples of preferred low-melting compounds from the class of lipase-degradable substances are hard fats, which consist for example of a mixture of mono-, di- and triglycerides, which can be obtained by esterification of fatty acids of natural origin with glycerol or by transesterification of fats of natural origin ,
  • hard fats are described in the Pharmacopoea Europaea (Ph. Eur. 8th Edition, Base Work 2014) and can be described, for example, under the name Witepsol E85, Witepsol H5, Witepsol H12, Witepsol H37 and / or Witepsol H15 from IOI Oleo GmbH ( Germany).
  • Preferred refractory compounds from the class of lipase-degradable substances may be selected from Dynasan 12, Dynasan 16 and / or Dynasan 118. These are available, for example, from IOI Oleo GmbH (Germany).
  • extruded depot forms may also comprise more than two compounds from the class of lipase degradable substances.
  • the ratio of low melting compound to high melting compound refers to the dry weight fraction of all low melting compounds on the dry weight fraction of all high melting compounds. This ratio is in the range of about 1: 9 to about 9: 1, more preferably in the range of about 1: 6 to about 6: 1, more preferably in the range of about 1: 3 to about 5: 1.
  • At least one active ingredient is included.
  • This at least one active agent is, without limitation, selected from the class of antibiotics, antimicrobials, antimycotics, antiseptics, chemotherapeutics, cytostatics, metastasis inhibitors, antiallergic agents, anticoagulants, sex hormones, sex hormone inhibitors, hemostyptics, hormones, peptide hormones, antidepressants, vaccines, gonadotropin Releasing Hormone Analogs, Growth Factor Inhibitors, Hormone Mimetics, Multiple Sclerosis Therapeutics, Programmed Cell Death Receptor 1 Antagonists (Programmed Cell Death Receptor 1 Antagonists), Neuroleptics, Complement System Inhibitors, Vitamins, Antihistamines, Antibodies, DNA, Plasmid DNA, cationic DNA complexes and RNA (such as siRNA or mRNA), fusion proteins and antidiabetics.
  • Useful agents include, but are not limited to, heparin, heparin derivatives, hirudin, acetylsalicylic acid, enoxaparin, liraglutide, albiglutide, dulaglutide, lixisenatide, exenatide, insulin, insulin analogs, acarbose, glatiramer acetate, octreotide, desmopressin, oxytocin, zafirlukast, buserelin, somatostatin, glibenclamide , Gliclazide, glimepiride, gliquidone, pioglitazone, miglitol, nateglinide, mitiglinide, repaglinide, sitagliptin, vildagliptin, dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, mesalazine,
  • Preferred extruded depot forms containing at least one active ingredient may be used for the treatment of cancers such as multiple myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, acute myeloid lymphoma, follicular lymphoma, chronic lymphocytic leukemia, breast, lung, endometrial, ovarian , Gastric, cervical or prostate cancer, pancreatic carcinoma, glioblastoma, renal carcinoma, hepatocellular carcinoma, colon carcinoma, neuroendocrine tumors, head and neck tumors, sarcoma, tumor syndromes resulting directly or indirectly from genetic defects in tumor suppressor genes such as P53, PTEN or VHL, endometrial carcinoma, lymphangioleiomyomatosis, neurofibromatosis 1, von Hippel-Lindau disease, as well as rheumatoid arthritis, ankylosing spondylitis (Ankylosing spondylitis), psoriatic arthritis, psoria
  • an advantageous extruded depot form contains at least one active substance from the class of monoclonal antibodies, neuroleptics or antidiabetic agents, more preferably from the class of type 1 antidiabetics and / or type 2 antidiabetic agents, particularly preferably from the class of incretin mimetics ,
  • the at least one active ingredient is selected from bevacizumab, ranibizumab, citalopram, risperidone, insulin and / or glucagon-like peptide 1 (GLP-I) analogs such as liraglutide, albiglutide, dulaglutide, lixisenatide and / or exenatide, in particular from bevacizumab, risperidone or exenatide, more preferably from bevacizumab and / or exenatide.
  • GLP-I glucagon-like peptide 1
  • preferred depot forms are used for the treatment of macular degeneration or diabetes mellitus, particularly preferably for the treatment of type 1 diabetes mellitus and type 2 diabetes mellitus, particularly preferably for the treatment of type 2 diabetes mellitus.
  • the particularly preferred active ingredient exenatide may advantageously comprise a polypeptide of 39 amino acids with the following sequence:
  • the at least one active ingredient may also be contained in various forms in the depot form, depending on which form gives the optimal release property of the active ingredient from the depot form.
  • Amino acid-based drugs can generally be considered as Cyclopeptide, oligopeptide or polypeptide or other pharmacologically acceptable derivatives or as components of molecular complexes.
  • the amino acids can be linked to one another via a-peptide bonds as well as via ⁇ -peptide bonds.
  • the at least one active ingredient can also be in the form of a salt, for example as an acetate, or else in the form of the free base or acid.
  • At least one of the amino acids of the amino acid-based active compounds mentioned above as preferred active compounds can have post-translational modifications.
  • these post-translational modifications advantageously do not influence the properties of the active substance, in particular with regard to release and action.
  • the content of the active substance in the depot form according to the invention can vary within a wide range.
  • An advantageous amount of active ingredient preferably of monoclonal antibodies, growth factor inhibitors or antidiabetics, more preferably of VEGF inhibitors or antidiabetics from the class of Inkretinmimetika, in particular Bevacizumab, Ranibizumab or exenatide, particularly preferably bevacizumab or exenatide, is about 0.3 wt from about% to about 50%, preferably from about 3% to about 30%, more preferably from about 4% to about 25%, more preferably about 7% by weight. -% to about 20 wt .-%.
  • the drug concentration of the active drug that prevails after administration of a depot form in the user's blood is important.
  • a substantially constant plasma concentration of the active ingredient of at least 50 pg / mL over a period of at least one week to a maximum of 12 months, preferably of at least one week to six Months to be achieved.
  • Extruded depot molds according to the invention are also suitable for cosmetic applications. In particular, an advantageous depot form for cosmetic wrinkle smoothing can be used.
  • the composition of the invention for local, in particular for targeted wrinkle smoothing used, particularly preferably for the prevention of wrinkles, for skin tightening and for protection against skin aging.
  • active substances for this purpose can be selected from hyaluronic acid, collagen and / or Botox.
  • Advantageous depot forms may moreover contain at least one adjuvant customary for subcutaneous administration forms, which modulates the release of active ingredient. These include, in particular, substances which are used in the production of subcutaneous implants and are physiologically harmless.
  • the excipients have high biocompatibility, so that the excipients and any degradation products of the excipients are not toxic to the user and do not cause undesirable side effects.
  • pore-forming agents can advantageously improve the delivery of the at least one active substance from the subcutaneous depot form.
  • a pore-forming agent may be selected, for example, from the group of hydrophilic substances such as calcium sulfate, calcium hydrogenphosphate, sugars such as glucose, lactose, fructose, mannitol, trehalose, dextrins, maltodextrin, sucrose, sorbitol, xylitol, starch or derivatives thereof such as hydroxyethyl starch, polyvinylpyrrolidone, Polyethylene glycol such as PEG 6000 or PEG 8000, sodium chloride, sodium citrate, citric acid, hyaluronic acids, polyvinyl alcohol, polyacrylic acid and its derivatives, polymethacrylic acid and derivatives thereof, polymethyl methacrylate, polystyrene, copolymers with monomers of methyl methacrylate and styrene, and mixtures thereof
  • hydrophilic substances
  • Particularly preferred pore-forming agents are trehalose and / or hydroxyethyl starch and / or polyethylene glycol (PEG), which can be obtained, for example, from Clariant or Sigma-Aldrich (Austria).
  • PEG polyethylene glycol
  • the molecular weight of a pore-forming agent is preferably in the range from about 1 to about 20 kDa. More preferably, the molecular weight is in the range of about 3 to about 10 kDa, more preferably in the range of about 4 to about 8 kDa.
  • lactic acid-based organic substances such as poly (L-lactide), poly (D, L-lactide), poly (glycolide), poly (L-lactide-co-D, L-lactide), poly (L-lactide-co-glycolide), poly (D, L-lactide-co-glycolide), poly (meso-lactide), poly (D, L -lactide-co-trimethylene carbonate), poly (trimethylene carbonate), poly (epsilon-caprolactone), poly (L-lactide-co-meso-lactide), poly (L-lactide-co-epsilon) caprolactone), poly (D, L-lactide-co-meso-lactide), poly (D, L-lactide-co-epsilon) caprolactone), poly (D, L-lactide-co-meso-lactide), poly (D, L-lactide-co-epsilon-caprolactone
  • Particularly preferred release modulators here are poly (D, L-lactide) and poly (D, L-lactide-co-glycolide) (PLGA), which are available, for example, from Evonik Industries AG (Germany) under the designations R 202 H (US Pat. Poly (D, L-lactide)) or RG 502 H and RG 752 H (PLGA) are available.
  • a release modulator, in particular poly (D, L-lactide) or PLGA is contained in the depot form, then its molecular weight can in principle vary within a wide range. Preferably, however, the molecular weight is in the range of about 5 to about 100 kDa. More preferably, the molecular weight is in the range of about 7 to about 60 kDa, more preferably in the range of about 9 to about 40 kDa.
  • the drug delivery rate can be further increased by adding a swellable polymer which is preferably selected from collagen, gelatin and derivatives thereof, starch and its derivatives (preferably hydroxyethyl starch, hydroxypropyl starch, carboxymethyl starch), cellulose derivatives, chitin, chitosan and their derivatives, polyamides, polyhydroxy acids, Polyhydroxybutyrates, polyhydroxyvalerates, polycaprolactones and polydioxanones.
  • a particularly preferred swellable polymer is hydroxyethyl starch (HES) and can be obtained from Sigma Aldrich (Austria).
  • the molecular weight of a swellable polymer is in the range of about 50 to about 400 kDa. More preferably, the molecular weight is in the range of about 90 to about 300 kDa, more preferably in the range of about 130 to about 200 kDa.
  • the degree of substitution of HES ie the ratio of the number of modified with hydroxyalkyl groups glucose units to the total number of monomer units, in this case is in the range of about 0.1 to about 1.
  • the depot forms of the invention may contain other conventional adjuvants known in the art, such as Tocopherols, e.g. B. ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol and mixtures thereof (vitamin E), which are used in particular as antioxidants.
  • such an antioxidant inactivates reactive oxygen species in the depot form, thereby slowing or completely preventing oxidation of the drug, thereby providing improved stability of the drug and, thus, longer shelf life of the sustained release form during storage as well as during use
  • a content of one or more of the preferred adjuvants causes a controlled and sustained release of active ingredient from the preferred extruded depot form.
  • (V) optionally 1 to 79 wt .-% PLGA, preferably 5 to 65 wt .-% PLGA, and
  • composition comprises an extruded depot form
  • trehalose optionally 2.5 to 18% by weight of trehalose, preferably 3 to 16% by weight of trehalose, in particular 3.5 to 15% by weight of trehalose,
  • the constituents of an extruded depot form are selected from
  • an advantageous active ingredient content is about 6 to 14% by weight
  • a content of a low-melting compound is about 42 to 60% by weight
  • a content of a high-melting compound is about 40% by weight.
  • trehalose may be wholly or partially replaced by HES.
  • extruded depot molds according to the invention are produced by extrusion. It has been found that the properties of the mixture prepared for extrusion of at least two compounds from the class of lipase-degradable substances with the at least one active ingredient improved when the active ingredient as a dried powder, preferably as a spray- or freeze-dried powder or Lyophilisate to which at least two compounds from the class of lipase-degradable substances is added. Insofar as active ingredients are obtained in a dissolved state, before the mixing of the substances for the production of the depot form according to the invention, preferably a drying step is carried out, in particular a lyophilization step.
  • cryoprocessors or lyoprotectors Lyo protectors in this context serving to protect the substances during drying and cryoprotectants have a corresponding task during freezing.
  • Lyo protectors in this context serving to protect the substances during drying and cryoprotectants have a corresponding task during freezing.
  • the length of the drug release after subcutaneous administration can be influenced by the extrudates immediately after the extrusion not cooled to ambient temperature, but stored for example in a drying oven or incubator for a certain time at elevated temperature.
  • a period of time in the range of about 0.5 to about 5 hours has proven to be advantageous.
  • the optional storage at elevated temperature depends on the melting point of the low-melting lipid and is for example in the range of about 30 to about 60 ° C, preferably about 35 to about 50 ° C, more preferably about 37 to 47 ° C.
  • preferred depot forms can be produced by a rounding process, in particular by spheronization.
  • the cylindrical extrudate is advantageously rounded off in such a way that any shapes formed during extrusion, such as, for example, corners and edges, which may adversely affect the application properties, are removed.
  • the spheronization can also be used for the production of microparticles, which are subsequently administered subcutaneously and thus also represent a biodegradable depot form.
  • a depot form has a homogeneous coating which consists of at least one layer applied to the core and advantageously limits the initial release thrust of active ingredient from the depot form and ensures therapeutic concentrations of the at least one active ingredient over a sustained period of time.
  • a preferred coating comprises a mixture of substances or a composition which is or are selected from at least one of the abovementioned components a) to c) of the depot form according to the invention, and thus may, for example, also be free of active substance.
  • the coating contains an active ingredient, its content may be the same or different than the active ingredient content of the core. In a particularly preferred embodiment, however, the coating is designed without active substance.
  • a suitable weight of an extruded depot mold moves in a range usual for subcutaneous implants.
  • the weight of the extruded depot form is also dependent on the desired application time and / or the place of application.
  • a preferred weight of an extruded depot form is in the range of 1 to 1000 mg, more preferably in the range of 5 to 100 mg, more preferably in the range of 7.5 to 75 mg, most preferably in the range of 10 to 60 mg.
  • a depot form according to the invention can be configured as a rod, sphere, cube, ellipsoid, cuboid, cushion, cylinder, tablet, pellet, platelets or briquette.
  • Depot molds according to the invention preferably have an injectable size, but may, if desired, also be introduced at the site of administration by means of a surgical procedure.
  • preferred depot forms have a diameter of at least 0.1 to 10 mm and a length of at least 0.15 to 50 mm.
  • depot molds have a diameter of at least 0.15 to 7.5 mm and a length of at least 0.2 to 45 mm, more preferably a diameter of at least 0.2 to 5 mm and a length of at least 0.3 to 40 mm ,
  • the diameter of the round or nearly round particles can be about 1 to about 100 ⁇ m, preferably about 5 to about 90 ⁇ m, particularly preferably about 10 to about 80 ⁇ m.
  • diameter refers to the longest path extending orthogonally to a rotation axis, which connects two points of the edge of the relevant body.
  • length refers to that part of the axis of rotation that is inside the body of revolution.
  • the ratio of diameter to length of preferred depot forms is advantageously in the range from 1:30 to 10: 1, preferably in the range from 1:15 to 5: 1, particularly preferably in the range from 1: 13.3 to 1: 1.
  • a process according to the invention for producing the extruded depot form comprises mixing (a) the at least one active substance, (b) the at least two compounds from the class of lipase-degradable substances and optionally (c) at least one adjuvant a homogeneous powder mixture is obtained.
  • the extruded depot mold is produced by means of the so-called double extrusion, which is characterized in that a second extrusion takes place after the first extrusion of the mixture according to step (ii) of the method explained above.
  • Such a preferred method comprises the following steps:
  • step (iii) optionally cutting the extrudate from step (ii) into pieces of suitable size
  • extrusion in particular melt extrusion, at a temperature below the melting point of the refractory compound
  • the diameter of the depot mold intended for use is advantageously adjusted in the course of the second extrusion, whereby a better homogeneity of the extrudate can be obtained.
  • a first and / or a second extrusion can take place with the aid of a screw extruder, as available, for example, under the name Mini CTW from Thermo Fisher Scientific GmbH (Karlsruhe, Germany). It can be used advantageously for a first and / or a second extrusion co-rotating or counter-rotating screws. Particularly preferred are for a first Extrusion corotating screws and used for a second extrusion counter-rotor checks.
  • the extrudate can be cut after the first extrusion. After the second extrusion or after the double extrusion, the extrudate is advantageously cut into implants or pieces of suitable length or further processed into microparticles by comminution, for example with the aid of a homogenizer or a cryogenic grinding.
  • a powder mixture is understood here to mean a mixture of a plurality of solid constituents of suitable size, it being possible for the constituents to have particles of a size of less than 1 nm.
  • a powder mixture can also have particles with a size in the range of 1 nm to 1 ⁇ m and / or particles with a size of more than 1 ⁇ m. Insofar as at least one of the constituents to be mixed is not present in solid form prior to mixing, it can be converted into the solid state before preparation of the powder mixture, for example by spray drying or freeze drying.
  • depot forms according to the invention can be administered, for example, by syringes, cannulas, applicators and injectors, in particular by applicators.
  • the present invention also relates to a kit comprising an extruded depot form according to the invention and an applicator suitable for application, with which the depot form can be administered subcutaneously.
  • extruded depot forms according to the invention need not necessarily be sterilized prior to incorporation into the applicator or generally be prepared under aseptic conditions, but may also be subjected to a sterilization process in the final container within the applicator.
  • an applicator is capable of receiving extruded depot molds of different lengths.
  • depot molds which have no cylindrical shape but, for example, are cuboidal or round or the like.
  • such an applicator has a hollow needle for receiving extruded depot molds with the above-described dimensions and a protective cap, which is to be removed before the application and can be fixed again after use.
  • the extruded depot mold is advantageously protected from external influences which may adversely affect the preferred application in any way.
  • Figure 1 shows release profiles of depot forms according to the invention with different exenatide-containing formulations which have a diameter of about 1, 5 mm.
  • FIG. 2 shows release profiles of depot forms according to the invention containing bevacizumab, which have a diameter of about 1, 9 mm.
  • FIG. 3 illustrates release profiles of depot forms according to the invention containing IgG1 antibodies which have a diameter of approximately 1.9 mm.
  • FIG. 4 illustrates a release profile of a depot form containing IgG1 antibodies according to the invention which has a diameter of approximately 1.5 mm and a length of 2 cm.
  • FIG. 5 shows a release profile of a depot form according to the invention containing exenatide.
  • the depot shape was produced by means of a double extrusion, has a diameter of 1, 2 mm and a length of 1, 5 cm.
  • lipid pellets from a low-melting hard fat (Witepsol E85, IOI Oleo GmbH, Hamburg, Germany) and a high-melting triglyceride (Dynasan 1 18, IOI Oleo GmbH, Hamburg, Germany) were cryo-milled separately (Freezer / Mill, C3 process). and Analysentechnik GmbH, Haar near Kunststoff, Germany) and then mixed 45% by weight of the high-melting triglyceride and 45% by weight of the low-melting hard fat with 10% by weight of exenatide lyophilizate (Bachem, Bubendorf, Switzerland) to give a homogeneous mixture (Speedmixer, Hauschild, Hamm, Germany).
  • extrusion was carried out by co-rotating screw extrusion (Mini CTW, Thermo Fisher Scientific GmbH, Düsseldorf, Germany) at 35 to 42 ° C and a screw speed of 40 rpm.
  • the diameter of the extrudate was adjusted to 1 .5 mm with a nozzle.
  • this can be followed by an annealing step, the temperature of which depends on the melting point of the low-melting lipid and is about 35 to 45 ° C.
  • the extrudate strand can be cut into extrudates of suitable length. Alternatively, the extrudate can be spheronized to microparticles.
  • Example 2 Example 2:
  • the preparation was carried out according to Example 1, but the composition of the depot forms according to the invention was supplemented with trehalose (Sigma Aldrich, Vienna, Austria).
  • the powder mixture consisted of 40 wt .-% of a high melting triglyceride (Dynasan 1 18, IOI Oleo GmbH, Hamburg, Germany), 40 wt .-% of a low-melting hard fat (Witepsol E85, IOI Oleo GmbH, Hamburg, Germany), 10 wt. % Trehalose and 10% by weight exenatide lyophilisate (Bachem, Bubendorf, Switzerland).
  • the preparation was again carried out according to Example 1, wherein additionally PLGA was incorporated into the matrix.
  • the powder mixture consisted of 35% by weight of a high-melting triglyceride (Dynasan 1 18, IOI Oleo GmbH, Hamburg, Germany), 35% by weight of a low-melting hard fat (Witepsol E85, IOI Oleo GmbH, Hamburg, Germany), 20 % By weight PLGA (Evonik Industries AG, Essen, Germany) and 10% by weight exenatide lyophilisate (Bachem, Bubendorf, Switzerland).
  • exemplary depot molds of the present invention in the appropriate shape and size (e.g., cut into cylinders of 1, 5 to 2 cm in length) were first individually weighed.
  • the depot forms of the invention were placed in release cells and mixed with 25 mL release medium (50 mM phosphate buffer). At the time of each sampling point, a complete replacement of the release medium occurred. The release rates were determined by UV-metric analysis.
  • lipid pellets of Witepsol H12 and Dynasan 1 18 were cryo-milled in a ratio of 1: 1. 90% by weight of the resulting powder mixture was then provided with 10% bevacizumab lyophilisate (eg lyophilised Avastin®, Roche, Basel, Switzerland) and processed to a homogeneous mixture.
  • bevacizumab lyophilisate eg lyophilised Avastin®, Roche, Basel, Switzerland
  • exemplary depot forms according to the invention in the respectively suitable shape and size eg cut into cylinders of 1, 5 to 2 cm in length
  • the depot forms according to the invention were placed in 2 ml Eppendorf tubes and the release was analyzed on a horizontal shaker (40 rpm) at 37 ° C. in PBS buffer (pH 7.4). Samples were taken at the time of measurement.
  • the active ingredient content was then determined at 280 nm with a UV-Vis spectrometer (Agilent, Böblingen,
  • lipid pellets from a low-melting hard fat (Witepsol E85, IOI Oleo GmbH, Hamburg, Germany) and a high-melting triglyceride (Dynasan 1 18, IOI Oleo GmbH, Hamburg, Germany) were cryo-milled separately (Freezer / Mill, C3 process).
  • extrusion was carried out by countercurrent screw melt extrusion (Mini CTW, Thermo Fisher Scientific GmbH, Düsseldorf, Germany) at 38 to 40 ° C and a screw speed of 20 rpm.
  • extruded a second time under the same conditions.
  • the diameter of the extrudate was adjusted to 1 .5 mm with a nozzle.
  • an annealing step may follow, the temperature of which depends on the melting point of the low-melting lipid and is about 40 to 45 ° C.
  • the extrudate strand was cut into extrudates of suitable length.
  • the extrudate can be spheronized to microparticles.
  • lipid pellets from a low-melting hard fat (Witepsol E85, IOI Oleo GmbH, Hamburg, Germany) and a high-melting triglyceride (Dynasan 1 18, IOI Oleo GmbH, Hamburg, Germany) were cryo-milled separately (Freezer / Mill, C3 process).
  • the diameter of the extrudate was adjusted to 1 .5 mm with a nozzle.
  • an annealing step may follow, the temperature of which depends on the melting point of the low-melting lipid and is about 40 to 45 ° C.
  • the extrudate strand was cut into extrudates of suitable length.
  • the extrudate can be spheronized to microparticles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une forme dépôt extrudée pour la libération prolongée de substance active comprenant au moins une substance active, au moins deux composés provenant de la classe des substances pouvant être dégradées par les lipases, les deux composés ou plus comprenant un composé à bas point de fusion et un composé à point de fusion élevé, le rapport entre le composé à bas point de fusion et le composé à point de fusion élevé se situant dans la plage de 1:9 à 9:1, et le cas échéant au moins un auxiliaire pour la modulation de la libération de la substance active, b) ou le cas échéant b) et c) comprenant au moins 60 % en poids de la masse sèche de la forme dépôt.
EP18714741.8A 2017-03-22 2018-03-22 Forme dépôt extrudée pour la libération prolongée de substance active Pending EP3600243A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102017106216.5A DE102017106216A1 (de) 2017-03-22 2017-03-22 Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
PCT/EP2018/057378 WO2018172494A1 (fr) 2017-03-22 2018-03-22 Forme dépôt extrudée pour la libération prolongée de substance active

Publications (1)

Publication Number Publication Date
EP3600243A1 true EP3600243A1 (fr) 2020-02-05

Family

ID=61837745

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18714741.8A Pending EP3600243A1 (fr) 2017-03-22 2018-03-22 Forme dépôt extrudée pour la libération prolongée de substance active

Country Status (5)

Country Link
US (1) US20200093736A1 (fr)
EP (1) EP3600243A1 (fr)
CN (1) CN110582268A (fr)
DE (1) DE102017106216A1 (fr)
WO (1) WO2018172494A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
WO2019071243A1 (fr) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Dépôts implantabes pour la libération contrôlée d'agents thérapeutiques
US20220183964A1 (en) * 2019-04-11 2022-06-16 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled, sustained release of therapeutic agents
CA3153224A1 (fr) * 2019-09-19 2021-03-25 Amw Gmbh Forme de depot extrudee pour la liberation controlee de substance active
CN112121152B (zh) * 2020-09-25 2021-06-22 南京大学 利司那肽在制备抗肿瘤药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
DK1539101T3 (da) 2002-07-31 2009-04-27 Alza Corp Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
KR100486028B1 (ko) 2004-04-20 2005-05-03 주식회사 펩트론 단백질 함유 서방성 리피드 임플란트 및 이의 제조방법
CA2652314A1 (fr) * 2006-05-17 2007-11-22 Ziscoat Nv Triglycerides d'acides gras utilises pour former des revetements biocompatibles
ES2441550T3 (es) * 2007-12-21 2014-02-05 Ludwig-Maximilians-Universität Dispositivos extruidos con forma de varilla para la Iiberación controlada de sustancias biológicas a humanos y animales
CN102440966A (zh) * 2010-10-06 2012-05-09 段明华 艾塞那肽缓释制剂的制备工艺研究
CA2877056A1 (fr) * 2012-07-01 2014-01-09 Novo Nordisk A/S Utilisation de peptides glp-1 a action longue
CN107106509B (zh) * 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 用于递送酸敏感药物的药物递送系统
CN105878191B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 缓释微粒的制备方法、制得的缓释微粒及其应用

Also Published As

Publication number Publication date
CN110582268A (zh) 2019-12-17
US20200093736A1 (en) 2020-03-26
WO2018172494A1 (fr) 2018-09-27
DE102017106216A1 (de) 2018-09-27

Similar Documents

Publication Publication Date Title
EP3600243A1 (fr) Forme dépôt extrudée pour la libération prolongée de substance active
EP1248596B1 (fr) Kit a implantation comprenant une phase de support et un solvent
DE60003803T2 (de) Trockene formbare arzneistoffformulierung
JP5795606B2 (ja) リスペリドン化合物の徐放送達製剤
DE69212497T2 (de) Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe
ES2637795T3 (es) Material de administración de fármacos hidrofóbico, método para la fabricación del mismo y métodos para la administración de una composición de administración de fármacos
EP0311065B1 (fr) Système implantable biodégradable pour la délivrance d'un agent actif
EP0650354B1 (fr) Solutions solides et liquides de substances medicamenteuses peu solubles dans l'eau
PL206594B1 (pl) Kompozycja implantu śródocznego i zastosowanie leku oftalmicznego w połączeniu z niskocząsteczkowym związkiem lipofilowym do jej wytwarzania
EP1267828B1 (fr) Formulations pharmaceutiques comprenant des esters d'acides gras et de saccharose pour contrôler la liberation des agents actifs
DE69819145T2 (de) Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
DE69013797T2 (de) Gehirnspezifische Zubereitung mit gesteuerter Abgabe.
KR20220112737A (ko) 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법
US20080300322A1 (en) Delivery vehicles containing rosin resins
EP2760437A1 (fr) Système de pulvérisation permettant de produire une matrice formée in situ
Sax et al. In-vivo biodegradation of extruded lipid implants in rabbits
DE102020124431A1 (de) Extrudierte Depotform mit kontrollierter Wirkstofffreisetzung
US20200316208A1 (en) Mechanical processing of biopolymers
CN111012734B (zh) 一种载药网状原位相变凝胶缓释系统及其制备方法
Chakraborty et al. Silk fibroin: A smart biomaterial for long term and targeted nanotherapeutics
US20160151286A1 (en) Hydrophilic Microparticles, Drug-Delivery Material, Method For Manufacturing Thereof And Methods For Delivery of A Drug-Delivery Composition
DE10001682A1 (de) Partikel/Implantate

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220503